Clostridium difficile bacteria, computer illustration. C. difficile is a normal inhabitant of the human intestine, but it can become a pathogen when antibiotics disrupt the normal intestinal flora and ...

Scientists have discovered that the gut-infecting bacterium Clostridium difficile is evolving into two separate species, with one group highly adapted to spread in hospitals. Researchers at the ...

The close-knit, flexible outer layer - like chain mail - which protects superbug C.difficile has been unveiled. The spectacular structure of the protective armour of superbug C.difficile has been ...

We conducted a phase 3, double-blind, randomized, placebo-controlled trial in which patients who had had three or more episodes of C. difficile infection (inclusive of the qualifying acute episode) ...

STATEN ISLAND, N.Y., Dec. 9, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule ...

Clostridiodes difficile infection has become a leading cause of severe, sometimes fatal diarrheal illness, with the bacterium's toxins causing the damage. New work cements our knowledge of how C. diff ...

SAINT-PREX, Switzerland & ROSEVILLE, Minn.--(BUSINESS WIRE)--Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today presented results from the pivotal Phase 3 PUNCH™ CD3 clinical trial, ...

(RTTNews) - Acurx Pharmaceuticals, Inc. (ACXP) Monday announced that its lead antibiotic candidate, ibezapolstat, is advancing to international Phase 3 clinical trials for treating C. difficile ...

Exposure to C. difficile in infancy produces an immune response that might protect against this gastrointestinal infection later in childhood, according to a study published in Clinical Infectious ...

Data from the phase 3 study confirmed the lot consistency, immunogenicity, safety, and tolerability of a toxoid-based Clostridioides difficile vaccine. Neutralizing antibody responses 1 month after ...

HALETHORPE, Md., March 11, 2025 /PRNewswire/ -- Fzata, Inc. announces the execution of a clinical trial agreement with the National Institutes of Health (NIH) to sponsor a Phase 1 clinical trial of ...